|Description||HDAC-IN-2, a selective HDAC inhibitor, has been found to probably restrain the transcription and division of tumor oncogene and could also lead to the apoptosis of tumor cells.It is under Phase II trials against Multiple myeloma. IC50: 4 nM and 76 nM for|
|Synonyms||HDAC-IN-2; 2-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-441P620G3P; 441P620G3P; Citarinostat|
|Solubility||DMSO: ≥ 30 mg/mL|
|Application||HDAC-IN-2 is a selective HDAC inhibitor that has been found to probably restrain the transcription and division of tumor oncogene and could also lead to the apoptosis of tumor cells.It is under Phase II trials against Multiple myeloma.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Acetylon Pharmaceuticals|
Rocilinostat is an orally bioavailable histone deacetylase 6 (HDAC6) inhibitor with potential antineoplastic activity. It selectively targets and binds to HDAC6...
Givinostat hydrochloride monohydrate
Givinostat, also known as ITF2357, is an orally active HDAC inhibitor (IC50= 198 and 157 nM for HDAC1 and HDAC3, respectively), with potential anti-inflammatory...
Tacedinaline, also known as CI-944, is an orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits his...
ST7612AA1 is a potent Histone deacetylase (HDCA) inhibitor. It showed an in vitro activity in the nanomolar range associated with a remarkable in vivo antitumor...
Dacinostat, also known as LAQ824, is a hydroxamate histone deacetylase inhibitor with potential anticancer activity. LAQ824 sensitized nonsmall cell lung cancer...
RGFP 109 is a histone deacetylase (HDAC) inhibitor that has shown to reverse FXN gene silencing in short-term studies of Friedreich ataxia (FRDA) patient cells.
TC-H 106 is a slow, tight-binding inhibitor of class I HDAC, including HDAC 1, 2, and 3 with IC50 values of 150 nM , 760nM, and 370 nM, respectively. It demonst...
ACY-738 is a potent and selective HDAC6 inhibitor with improved brain bioavailability. ACY-738 inhibits HDAC6 with low nanomolar potency and a selectivity of 60...
LMK-235 is a selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor. LMK-235 demonstrates activity against chemoresistant cancer cell lines in an MTT assa...
Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM ...
Sodium butyrate is the sodium salt of butyric acid, used in the culture of mammalian cells.
The hydrochloride salt form of Tinostamustine, a benzimidazol derivative, has been found to be a HDAC inhibitor and could probably be effective against sorts of...
Trichostatin A, also known as TSA, is a HDAC inhibitor. TSA inhibits the eukaryotic cell cycle during the beginning of the growth stage. TSA can be used to alte...
Tubastatin A is selective at all isozymes except HDAC8 and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately...
Phenylbutyrate is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects.
(-)-Parthenolide is a sesquiterpene lactone which occurs naturally in the plant feverfew(Tanacetum parthenium) and also promotes the ubiquitination of MDM2 and ...
BG45 is a class I HDAC inhibitor with IC50 of 289 nM, 2.0 µM, 2.2 µM and >20 µM for HDAC3, HDAC1, HDAC2, and HDAC6 in cell-free assays, respectively.
Belinostat is a novel pan-HDAC inhibitor with IC50 of 27 nM, with activity demonstrated in cisplatin-resistant tumors. It inhibits the growth of tumor cells wit...
WT-161 is a potent and specific HDAC6 inhibitor (IC50= 0.40 nM). Consistent with WT-161 mediated hyperacetylation and inhibition of hsp90 chaperone function, tr...